Research Ebit Per Revenue vs Capex To Revenue Analysis

RSSS Stock

USD 3.25 0.17 5.52%

Research Solutions financial indicator trend analysis is much more than just breaking down Research Solutions prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Research Solutions is a good investment. Please check the relationship between Research Solutions Ebit Per Revenue and its Capex To Revenue accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Research Solutions. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more information on how to buy Research Stock please use our How to Invest in Research Solutions guide.

Ebit Per Revenue vs Capex To Revenue

Ebit Per Revenue vs Capex To Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Research Solutions Ebit Per Revenue account and Capex To Revenue. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Research Solutions' Ebit Per Revenue and Capex To Revenue is -0.53. Overlapping area represents the amount of variation of Ebit Per Revenue that can explain the historical movement of Capex To Revenue in the same time period over historical financial statements of Research Solutions, assuming nothing else is changed. The correlation between historical values of Research Solutions' Ebit Per Revenue and Capex To Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebit Per Revenue of Research Solutions are associated (or correlated) with its Capex To Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Revenue has no effect on the direction of Ebit Per Revenue i.e., Research Solutions' Ebit Per Revenue and Capex To Revenue go up and down completely randomly.

Correlation Coefficient

-0.53

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Ebit Per Revenue

Capex To Revenue

The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.

Most indicators from Research Solutions' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Research Solutions current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Research Solutions. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more information on how to buy Research Stock please use our How to Invest in Research Solutions guide.At this time, Research Solutions' Tax Provision is comparatively stable compared to the past year. Enterprise Value Over EBITDA is likely to gain to 1,080 in 2024, whereas Discontinued Operations is likely to drop slightly above 100.4 K in 2024.

	2021	2023	2024 (projected)
Interest Expense	136.7K	157.3K	82.5K
Depreciation And Amortization	17.7K	836.3K	878.1K

Interest Expense Depreciation And Amortization

Research Solutions fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Total Equity	Common Stock Shares Outstanding	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock
Total Assets		-0.26	0.7	0.64	0.89	-0.34	0.92	-0.4	-0.68	0.32	0.35	0.93	0.33	0.51	0.93	0.5	0.54	0.47	0.81	0.59	0.98	0.36	0.48	-0.61	0.94	0.59
Short Long Term Debt Total	-0.26		-0.54	0.04	-0.54	0.89	-0.45	0.49	0.25	0.31	-0.35	-0.18	-0.41	0.32	-0.22	-0.41	-0.37	-0.36	-0.44	-0.38	-0.11	0.5	-0.25	0.07	-0.24	-0.42
Other Current Liab	0.7	-0.54		0.48	0.82	-0.72	0.8	-0.75	-0.79	-0.03	0.68	0.48	0.65	0.43	0.52	0.81	0.79	0.68	0.62	0.8	0.59	-0.09	0.69	-0.11	0.54	0.84
Total Current Liabilities	0.64	0.04	0.48		0.43	-0.07	0.69	-0.55	-0.75	0.66	0.61	0.43	0.54	0.78	0.42	0.68	0.76	0.51	0.56	0.79	0.69	0.61	0.76	-0.12	0.44	0.74
Total Stockholder Equity	0.89	-0.54	0.82	0.43		-0.63	0.89	-0.56	-0.56	0.01	0.47	0.77	0.5	0.27	0.79	0.59	0.54	0.51	0.68	0.61	0.77	0.06	0.53	-0.45	0.81	0.66
Property Plant And Equipment Net	-0.34	0.89	-0.72	-0.07	-0.63		-0.54	0.63	0.37	0.15	-0.5	-0.2	-0.54	0.13	-0.25	-0.54	-0.45	-0.35	-0.42	-0.5	-0.18	0.53	-0.41	-0.09	-0.27	-0.55
Current Deferred Revenue	0.92	-0.45	0.8	0.69	0.89	-0.54		-0.67	-0.77	0.27	0.61	0.75	0.61	0.41	0.76	0.66	0.73	0.67	0.79	0.73	0.87	0.27	0.69	-0.38	0.79	0.75
Net Debt	-0.4	0.49	-0.75	-0.55	-0.56	0.63	-0.67		0.68	-0.14	-0.99	-0.04	-0.98	-0.31	-0.07	-0.8	-0.83	-0.73	-0.39	-0.77	-0.3	0.03	-0.95	-0.32	-0.1	-0.83
Retained Earnings	-0.68	0.25	-0.79	-0.75	-0.56	0.37	-0.77	0.68		-0.32	-0.67	-0.46	-0.57	-0.7	-0.48	-0.84	-0.9	-0.76	-0.7	-0.88	-0.69	-0.2	-0.72	0.18	-0.5	-0.87
Accounts Payable	0.32	0.31	-0.03	0.66	0.01	0.15	0.27	-0.14	-0.32		0.19	0.23	0.13	0.58	0.21	0.12	0.18	-0.14	0.26	0.25	0.43	0.47	0.33	0.04	0.21	0.17
Cash	0.35	-0.35	0.68	0.61	0.47	-0.5	0.61	-0.99	-0.67	0.19		-0.03	0.99	0.37	-0.01	0.8	0.83	0.73	0.32	0.76	0.26	0.06	0.97	0.37	0.03	0.82
Non Current Assets Total	0.93	-0.18	0.48	0.43	0.77	-0.2	0.75	-0.04	-0.46	0.23	-0.03		-0.04	0.36	1.0	0.24	0.25	0.23	0.75	0.35	0.93	0.32	0.11	-0.81	1.0	0.32
Cash And Short Term Investments	0.33	-0.41	0.65	0.54	0.5	-0.54	0.61	-0.98	-0.57	0.13	0.99	-0.04		0.24	-0.01	0.74	0.77	0.71	0.28	0.7	0.23	0.03	0.94	0.37	0.02	0.77
Net Receivables	0.51	0.32	0.43	0.78	0.27	0.13	0.41	-0.31	-0.7	0.58	0.37	0.36	0.24		0.34	0.54	0.55	0.24	0.37	0.62	0.58	0.55	0.54	-0.06	0.34	0.57
Good Will	0.93	-0.22	0.52	0.42	0.79	-0.25	0.76	-0.07	-0.48	0.21	-0.01	1.0	-0.01	0.34		0.26	0.27	0.25	0.76	0.37	0.92	0.29	0.13	-0.8	1.0	0.35
Common Stock Total Equity	0.5	-0.41	0.81	0.68	0.59	-0.54	0.66	-0.8	-0.84	0.12	0.8	0.24	0.74	0.54	0.26		0.94	0.77	0.51	0.98	0.43	0.02	0.81	0.01	0.29	0.99
Common Stock Shares Outstanding	0.54	-0.37	0.79	0.76	0.54	-0.45	0.73	-0.83	-0.9	0.18	0.83	0.25	0.77	0.55	0.27	0.94		0.87	0.53	0.95	0.5	0.18	0.86	0.01	0.3	0.95
Inventory	0.47	-0.36	0.68	0.51	0.51	-0.35	0.67	-0.73	-0.76	-0.14	0.73	0.23	0.71	0.24	0.25	0.77	0.87		0.48	0.73	0.42	0.09	0.69	-0.15	0.28	0.77
Other Current Assets	0.81	-0.44	0.62	0.56	0.68	-0.42	0.79	-0.39	-0.7	0.26	0.32	0.75	0.28	0.37	0.76	0.51	0.53	0.48		0.58	0.81	0.11	0.39	-0.53	0.77	0.54
Other Stockholder Equity	0.59	-0.38	0.8	0.79	0.61	-0.5	0.73	-0.77	-0.88	0.25	0.76	0.35	0.7	0.62	0.37	0.98	0.95	0.73	0.58		0.54	0.15	0.81	-0.06	0.39	0.99
Total Liab	0.98	-0.11	0.59	0.69	0.77	-0.18	0.87	-0.3	-0.69	0.43	0.26	0.93	0.23	0.58	0.92	0.43	0.5	0.42	0.81	0.54		0.47	0.42	-0.64	0.93	0.52
Property Plant And Equipment Gross	0.36	0.5	-0.09	0.61	0.06	0.53	0.27	0.03	-0.2	0.47	0.06	0.32	0.03	0.55	0.29	0.02	0.18	0.09	0.11	0.15	0.47		0.24	-0.21	0.28	0.11
Total Current Assets	0.48	-0.25	0.69	0.76	0.53	-0.41	0.69	-0.95	-0.72	0.33	0.97	0.11	0.94	0.54	0.13	0.81	0.86	0.69	0.39	0.81	0.42	0.24		0.27	0.16	0.85
Short Term Debt	-0.61	0.07	-0.11	-0.12	-0.45	-0.09	-0.38	-0.32	0.18	0.04	0.37	-0.81	0.37	-0.06	-0.8	0.01	0.01	-0.15	-0.53	-0.06	-0.64	-0.21	0.27		-0.79	-0.03
Intangible Assets	0.94	-0.24	0.54	0.44	0.81	-0.27	0.79	-0.1	-0.5	0.21	0.03	1.0	0.02	0.34	1.0	0.29	0.3	0.28	0.77	0.39	0.93	0.28	0.16	-0.79		0.37
Common Stock	0.59	-0.42	0.84	0.74	0.66	-0.55	0.75	-0.83	-0.87	0.17	0.82	0.32	0.77	0.57	0.35	0.99	0.95	0.77	0.54	0.99	0.52	0.11	0.85	-0.03	0.37

Click cells to compare fundamentals

Research Solutions Account Relationship Matchups

Research Solutions fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	14.8M	16.9M	17.0M	21.8M	41.9M	44.0M
Other Current Liab	6.3M	6.7M	6.6M	8.1M	8.8M	9.3M
Total Current Liabilities	10.0M	11.5M	12.1M	14.5M	17.9M	9.3M
Total Stockholder Equity	4.9M	5.4M	4.9M	7.3M	11.7M	12.3M
Property Plant And Equipment Net	83.6K	20.8K	48.0K	70.2K	88.0K	83.6K
Current Deferred Revenue	3.5M	4.8M	5.5M	6.4M	9.0M	9.5M
Net Debt	(9.2M)	(11.0M)	(10.6M)	(13.5M)	(6.1M)	(6.4M)
Retained Earnings	(21.2M)	(21.5M)	(23.1M)	(22.5M)	(26.3M)	(25.0M)
Accounts Payable	6.3M	6.7M	6.6M	8.1M	8.8M	5.9M
Cash	9.3M	11.0M	10.6M	13.5M	6.1M	5.4M
Non Current Assets Total	89.8K	21.7K	48.9K	533.3K	27.2M	28.5M
Cash And Short Term Investments	9.3M	11.0M	10.6M	13.5M	6.1M	5.7M
Net Receivables	4.4M	4.7M	5.3M	6.2M	6.9M	5.4M
Common Stock Total Equity	24.0K	24.4K	26.0K	26.5K	30.5K	21.0K
Common Stock Shares Outstanding	24.8M	26.0M	26.4M	29.1M	28.9M	21.8M
Liabilities And Stockholders Equity	14.8M	16.9M	17.0M	21.8M	41.9M	44.0M
Other Current Assets	962.1K	1.2M	1.1M	400.3K	1.7M	1.8M
Other Stockholder Equity	26.1M	27.0M	28.1M	29.9M	38.1M	20.4M
Total Liab	10.0M	11.5M	12.1M	14.5M	30.2M	31.7M
Property Plant And Equipment Gross	83.6K	20.8K	889.0K	952.1K	1.0M	603.2K
Total Current Assets	14.7M	16.9M	17.0M	21.3M	14.7M	12.0M
Accumulated Other Comprehensive Income	(125.0K)	(119.6K)	(121.9K)	(118.2K)	(118.8K)	(124.8K)
Short Term Debt	79.3K	6.7M	6.6M	8.1M	(8.8M)	(8.4M)
Common Stock	26.0K	26.5K	27.1K	29.5K	32.3K	22.9K
Non Current Liabilities Total	79.3K	3.6M	4.8M	5.5M	12.3M	12.9M
Net Tangible Assets	4.9M	5.4M	4.9M	6.9M	7.9M	8.3M
Other Assets	6.2K	906.0	893.0	1.1K	946.8	899.46
Property Plant Equipment	83.6K	20.8K	48.0K	70.2K	63.2K	60.0K
Non Currrent Assets Other	6.2K	906.0	893.0	1.1K	981.0	931.95
Net Invested Capital	4.9M	5.4M	4.9M	7.3M	11.7M	6.2M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Research Stock Analysis

When running Research Solutions' price analysis, check to measure Research Solutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Research Solutions is operating at the current time. Most of Research Solutions' value examination focuses on studying past and present price action to predict the probability of Research Solutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Research Solutions' price. Additionally, you may evaluate how the addition of Research Solutions to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC